Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 9

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 9
---
 Merger were consummated.

“Merger Sub” means
A SPAC I Mini Sub Acquisition Corp., a Cayman Islands exempted company and former wholly-owned subsidiary of A SPAC I Mini Acquisition
Corp.

“Memorandum and Articles
of Association” means the Company’s Amended and Restated Memorandum and Articles of Association, as and restated on July 4,
2025.

“NewGenIvf” means
NewGenIvf Group Limited, a British Virgin Islands business company, the surviving entity of the Business Combination, unless the context
so requires.

“Ordinary Shares”
means the Class A Ordinary Shares and Class B Ordinary Shares.

“Preferred Shares”
means preferred shares of the Company, no par value per share.

“Reincorporation Merger”
means the first step of the Business Combination which occurred pursuant to the Merger Agreement, in which ASCA reincorporated to the
British Virgin Islands by merging with and into A SPAC I Mini Acquisition Corp.

“Reverse Stock Splits”
means the First Reverse Stock Split, the Second Reverse Stock Split, and the Third Reverse Stock Split. In this registration statement,
where we state historical share and per-share numbers, we have, where appropriate, reflected a retroactive adjustment due to the Reverse
Stock Splits in parentheses.

“Second Reverse Stock
Split” means the 1-for-10 reverse stock split effected by the Company on May 5, 2025.

“Third Reverse Stock
Split” means the 1-for-5 reverse stock split effected by the Company on August 4, 2025.

<div align='center'>iv

PROSPECTUS SUMMARY</div>

This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully, including the “Risk Factors” section and the financial statements and related notes appearing at the end of this prospectus.

Unless the context otherwise
requires, all references in this Prospectus Summary to “NewGenIvf,” “we,” “our,” and “us”
refer to Legacy NewGenIvf and its subsidiaries as they existed prior to the Closing if described in relation to a date prior to April
3, 2024. Any references to “NewGenIvf,” “we,” “our,” and “us” with respect to the present
time, a future time, or a date